Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line-Reference-Cited by-同舟云学术

Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line

Published:2019-08 Issue: Volume:166 Page:128-138
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Van Der Steen Nele,Leonetti Alessandro^ORCID,Keller Kaylee,Dekker Henk,Funel Niccola,Lardon Filip,Ruijtenbeek Rob,Tiseo Marcello,Rolfo Christian,Pauwels Patrick,Peters Godefridus J.,Giovannetti Elisa^ORCID

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference43 articles.

1. Cancer statistics, 2018, CA;Siegel;Cancer J. Clin.,2018

2. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?;Recondo;Nat. Rev. Clin. Oncol.,2018

3. Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer;Van Der Steen;Cancer Drug Resist.,2018

4. cMET in NSCLC: can we cut off the head of the hydra? From the pathway to the resistance;Van Der Steen;Cancers (Basel),2015

5. EGF receptor gene mutations are common in lung cancers from ‘never smokers’; and are associated with sensitivity of tumors to gefitinib and erlotinib;Pao;Proc. Natl. Acad. Sci.,2004

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Two-Dimensional and Spheroid-Based Three-Dimensional Cell Culture Systems: Implications for Drug Discovery in Cancer;Drugs and Drug Candidates;2024-06-13

2. Identification of protein biomarkers for prediction of response to platinum‐based treatment regimens in patients with non‐small cell lung cancer;Molecular Oncology;2024-01-25

3. A novel cross-gene cluster between ferroptosis and disulfidptosis for the prediction of prognosis, immunity and drug sensitivity in lung adenocarcinoma;New Medicine;2023-10-28

4. The therapeutic inhibition of topoisomerase inhibitor and crizotinib combination in EGFR wild and mutant lung cancer cells;Biochemical Pharmacology;2022-11

5. CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells;Frontiers in Oncology;2022-07-22